ADMA Biologics (NASDAQ:ADMA) Sees Large Volume Increase – What’s Next?

ADMA Biologics Inc (NASDAQ:ADMA) saw unusually-high trading volume on Wednesday . Approximately 7,005,279 shares changed hands during trading, an increase of 105% from the previous session’s volume of 3,412,795 shares.The stock last traded at $9.5370 and had previously closed at $11.33.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA publicly refuted Culper Research’s allegations, saying the short‑seller misunderstand the company’s business and the role of its ASCENIV product — the company’s rebuttal could stabilize investor sentiment if followed by clarifying disclosures. ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
• Positive Sentiment: Unusual bullish options activity was reported (large spike in call purchases), indicating some speculative or informed buyers are betting on a rebound or corrective move after the sell‑off.
• Neutral Sentiment: Some analysts and commentators note the stock may be oversold and technically poised for a bounce, but that view is contingent on resolution of the allegations and legal inquiries. Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
• Negative Sentiment: The Culper Research short report alleging channel stuffing appears to be the catalyst for the sell‑off; short reports can lead to sharp, sustained pressure until disproven. ADMA Biologics extends selloff as Cantor downgrades after short report
• Negative Sentiment: Multiple law firms and plaintiff‑side notices have announced securities‑fraud investigations and shareholder alerts (BFA Law, Glancy Prongay Wolke & Rotter, Pomerantz, Holzer & Holzer, Ademi LLP, others) — this increases potential litigation risk and ongoing headline pressure. ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report — Investors Notified to Contact BFA Law Securities-Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced
• Negative Sentiment: Cantor Fitzgerald and other market participants moved to downgrade or flag the name after the report, adding analyst pressure to the stock while investigations and media coverage continue. Cantor Fitzgerald downgrades ADMA Biologics (ADMA)

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research note on Thursday. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Price Performance

The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.97 billion, a PE ratio of 13.82 and a beta of 0.51. The stock has a 50-day moving average price of $15.76 and a 200 day moving average price of $16.47.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same quarter last year, the firm posted $0.46 EPS. The business’s revenue was up 18.4% on a year-over-year basis. Equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This represents a 2.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve Elms purchased 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the purchase, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently bought and sold shares of the company. Westfield Capital Management Co. LP acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $74,866,000. Janus Henderson Group PLC boosted its stake in shares of ADMA Biologics by 3,906.1% in the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after acquiring an additional 3,838,158 shares during the last quarter. Capital Research Global Investors increased its position in shares of ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after purchasing an additional 3,383,559 shares in the last quarter. Caligan Partners LP purchased a new stake in shares of ADMA Biologics during the third quarter worth approximately $38,653,000. Finally, UBS Group AG raised its stake in ADMA Biologics by 129.9% in the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after purchasing an additional 2,581,670 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.